Drug development in the field of oncology is mired in tradition, resulting in skyrocketing clinical trial costs that translate into increased costs of health care; the status quo is not sustainable.

The primary goal of the trial was to optimize radiation therapy (RT) dose among three levels (low, standard, and high), given either with placebo (P) or an investigational agent (A), for treating ...